- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Neoadjuvant Immunotherapy Promising in CRC, but Long-term Data Needed, Says Dr Kristen Ciombor
Kristen K Ciombor, MD, MSCI, associate professor at Vanderbilt University, explains that results of neoadjuvant immunotherapy in colorectal cancer are promising, but long-term data is still needed.
While not yet standard of care, neoadjuvant immunotherapy is showing positive responses in patients with colorectal cancer when using this type of experiemental approach, said Kirsten K. Ciombor, MD, MSCI, associate professor of medicine at Vanderbilt University, speaking at an Institute for Value-Based Medicine® meeting.
Transcript
What long-term survival data are you waiting to see in the use of neoadjuvant immunotherapy in colorectal cancer?
Neoadjuvant immunotherapy, it's still an experimental approach; it's not yet standard of care. But we're starting to see some really incredible responses, both in rectal cancer and colon cancer. We need to make sure that these responses, these tumor shrinkage data are really reliable, that they are reproducible, that they are generalizable to patients across the spectrum, and then of course, that they're durable.
We are hopeful that these early responses will translate to increased rates of cure, but we need more follow up data to ensure that's true.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Frameworks for Advancing Health Equity: Youth Behavioral Health Strategy Program
September 17th 2024Chris Barton, LCSW, of Horizon Blue Cross Blue Shield of New Jersey, explores how the Youth Behavioral Health Strategy program focuses on addressing the specific needs of youth with mental health and substance use issues through a comprehensive approach.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
ctDNA Response Predicts Outcomes in MSI-H mCRC Immunotherapy
June 18th 2025Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).
Read More
